Arcutis Biotherapeutics, Inc.
ARQT
Rangering i aksjer
#4009
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Aksjekurs
$32.58
Markedsverdi
$4.09B
Endring (1 dag)
2.15%
Endring (1 år)
56.02%
Land
US
Handel Arcutis Biotherapeutics, Inc. (ARQT)
Kategori
Healthcare
P/B-forhold for Arcutis Biotherapeutics, Inc. (ARQT)
P/B-forhold per October 2026 TTM: 15.63
Ifølge Arcutis Biotherapeutics, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 15.63. Ved slutten av 2023 hadde selskapet et P/B-forhold på 2.52.
P/B-historikk for Arcutis Biotherapeutics, Inc. fra 2017 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 15.63 | 46.05% |
| 2024 | 10.70 | 323.63% |
| 2023 | 2.52 | -35.03% |
| 2022 | 3.89 | 12.90% |
| 2021 | 3.44 | -7.15% |
| 2020 | 3.71 | -129.04% |
| 2019 | -12.77 | -61.23% |
| 2018 | -32.93 | 614.27% |
| 2017 | -4.61 | 0.00% |
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| 6.251 | -60.00% |
US
|
|
| 13.2547 | -15.18% |
US
|
|
| 4.208 | -73.07% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -60.44% |
NL
|
